Production (Stage)
Ernexa Therapeutics Inc.
ERNA
$2.29
-$0.08-3.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -23.39% | 6.40% | -375.84% | -22.65% | -22.73% |
| Total Depreciation and Amortization | -87.25% | -85.86% | -12.77% | 817.46% | 772.58% |
| Total Amortization of Deferred Charges | -- | 1,139.44% | 2,263.46% | -- | -- |
| Total Other Non-Cash Items | 525.48% | 57.88% | 8,109.74% | -23.23% | 18.98% |
| Change in Net Operating Assets | -76.94% | -404.70% | -206.35% | 5,252.94% | 166.22% |
| Cash from Operations | 44.89% | 23.94% | -7.88% | 41.66% | 38.06% |
| Capital Expenditure | -- | 100.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | -- | -- | -- |
| Total Debt Issued | 60.14% | -100.00% | -55.40% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | 0.00% | -- |
| Other Financing Activities | -- | -77.63% | 100.00% | -- | -- |
| Cash from Financing | 62.74% | -86.89% | -54.48% | -107.05% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.69% | -183.83% | -189.06% | 28.93% | 59.35% |